Scholarlink

<p>Synchronous mucinous metaplasia and neoplasia of the female genital tract (SMMN-FGT) is a rare disorder defined as mucinous lesions affecting at least two sites in the female genital tract. We report a case of SMMN-FGT in a Caucasian 65-year-old patient with a right adnexal mass. The patient underwent radical surgery and histological examination showed mucinous ovarian carcinoma combined with mucinous metaplasia of the fallopian tube. The carcinomatous infiltration also affected the left ovary, peritoneum, and omentum. Molecular analysis revealed a shared <i>STK11</i> mutation in both the ovarian carcinoma and tubal metaplasia, and other mutations (including <i>KRAS</i>) that differed between these tissues. The patient received adjuvant chemotherapy combined with bevacizumab. As there is limited experience with SMMN-FGT, standard diagnostic and treatment protocols have not yet been established. Although association with Peutz-Jeghers syndrome (PJS) was described, our patient had no clinical signs of PJS and the detected <i>STK11</i> mutation was likely somatic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synchronous mucinous metaplasia and neoplasia of the ovarium and fallopian tube with STK11 and KRAS mutations: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月3日

查看全文
  • Miroslava Flídrová,
  • Eva Krkavcová,
  • Nikola Hájková,
  • Kristýna Němejcová,
  • Pavel Dundr,
  • Michaela Kendall Bártů

摘要

Synchronous mucinous metaplasia and neoplasia of the female genital tract (SMMN-FGT) is a rare disorder defined as mucinous lesions affecting at least two sites in the female genital tract. We report a case of SMMN-FGT in a Caucasian 65-year-old patient with a right adnexal mass. The patient underwent radical surgery and histological examination showed mucinous ovarian carcinoma combined with mucinous metaplasia of the fallopian tube. The carcinomatous infiltration also affected the left ovary, peritoneum, and omentum. Molecular analysis revealed a shared STK11 mutation in both the ovarian carcinoma and tubal metaplasia, and other mutations (including KRAS) that differed between these tissues. The patient received adjuvant chemotherapy combined with bevacizumab. As there is limited experience with SMMN-FGT, standard diagnostic and treatment protocols have not yet been established. Although association with Peutz-Jeghers syndrome (PJS) was described, our patient had no clinical signs of PJS and the detected STK11 mutation was likely somatic.